Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Acasti Pharma Inc ACST

Healthcare
Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.


NDAQ:ACST - Post by User

Acasti Pharma Inc > Haywood at 7.4 millions stock.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Comment by boozehound3on May 10, 2019 9:19am
33 Views
Post# 29733377

RE:RE:RE:Haywood at 7.4 millions stock.

RE:RE:RE:Haywood at 7.4 millions stock. he will have paid a dollar us and received 8000000 warrants as well       he will be the anonymous seller as he will not be left with anything but the warrants before the end,  smart money doesn't risk 8 million dollars..

francine will be out of all his shraes and just hold the warrants as well

its just the way it is

 i don't think any large investor that got sucked into this thing with the amarin results is very happy.  i bet they are wondering why they ever put a nickel in.  large fund bought and was out a month later.  the rest are slowly trying to get out a the dollar level to limit losses.

i know you guys don't want to hear the facts but just look at todays news and think about it
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities